Internal R&D vs. CROs: AstraZeneca, Novartis Tout Advantages Of Staying In-House
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis reports savings of $100 mil. by decreasing its use of contract research organizations. AstraZeneca sees improved R&D productivity by relying less on CROs and by conducting clinical trials outside the U.S.